4//SEC Filing
Sabag Mark 4
Accession 0000950170-25-035512
CIK 0000818686other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:13 PM ET
Size
9.6 KB
Accession
0000950170-25-035512
Insider Transaction Report
Form 4
Sabag Mark
See "Remarks"
Transactions
- Award
Restricted Share Units
2025-03-05+62,893→ 62,893 total→ Ordinary Shares (62,893 underlying) - Exercise/Conversion
Restricted Share Units
2025-03-05−23,765→ 0 total→ Ordinary Shares (23,765 underlying) - Exercise/Conversion
Ordinary Shares
2025-03-05+23,765→ 488,911 total
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025.
- [F4]Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001721442
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:13 PM ET
- Size
- 9.6 KB